Anti-Human IL-6 (Sarilumab) – Fc Muted™ HRP
Anti-Human IL-6 (Sarilumab) – Fc Muted™ HRP
Product No.: LT1707
- -
- -
Product No.LT1707 Clone Hu137 Target IL-6 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2 Isotype Human IgG1κ Applications ELISA , FA , FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Product Concentration 0.5 mg/ml Formulation This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. <b> (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)</b> Storage and Handling This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2892934 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? B N IHC (Paraffin) IHC (Frozen) WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only. Antigen Distribution IL-6R is ubiquitously expressed. Background IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects. Antigen DetailsPubMed NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology . Innate Immunity . Neuroscience . Other Molecules References & Citations1. Kevzara (sarilumab) injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; Bridgewater, NJ: sanofi-aventis U.S.; May 2017. 2. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313. 3. "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020. Technical Protocols FA  |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT1700 | |
LT1703 | |
LT1704 | |
LT1702 | |
LT1701 | |
LT1711 | |
LT1706 | |
LT1705 | |
LT1707 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
